8-K: Compass Therapeutics Reports Strong 2025 Results, Pipeline Advances

Compass Therapeutics announced its 2025 financial results, highlighting significant pipeline progress including key clinical trial milestones and a strong cash position extending into 2028.

Summary

• Net loss for the year ended December 31, 2025, was $66.5 million, or $0.42 per common share, compared to $49.4 million, or $0.36 per common share, for 2024.
• Research and Development (R&D) expenses increased by 32% to $56.0 million in 2025, primarily due to manufacturing expenses for tovecimig ($7.7 million) and CTX-10726 ($5.9 million).
• General and Administrative (G&A) expenses increased by 12% to $16.9 million in 2025, driven by pre-commercialization expenses ($0.7 million) and advisory fees ($0.5 million).
• Cash and marketable securities totaled $209 million at year-end 2025, an increase of $82 million from $127 million at year-end 2024, providing an anticipated cash runway into 2028.
• The prespecified event threshold of 80% overall survival (OS) events for tovecimig in the Phase 2/3 COMPANION-002 study was reached in Q1 2026, with analyses of progression-free survival (PFS) and OS expected in April 2026.
• Expansion cohorts for CTX-8371 (PD-1 x PD-L1 bispecific antibody) are open for enrollment in patients with triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC), with initial data expected in Q2 2026.
• A new expansion cohort for CTX-8371 in Hodgkin lymphoma patients will begin shortly, based on a previously reported response.
• The IND application for CTX-10726 (PD-1 x VEGF-A bispecific antibody) received FDA clearance, and the Phase 1 study will be open for enrollment in Q1 2026, with clinical data expected in the second half of 2026.
• Initiation of the Phase 2 trial of CTX-471 (CD137 or 4-1BB agonist antibody) is expected in mid-2026.
• Bing Gong, PhD, has been promoted to Chief Scientific Officer (CSO), and Cyndi Sirard and Arjun Prasad have been welcomed as Chief Medical Officer (CMO) and Chief Commercial Officer (CCO), respectively.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive update, driven by significant clinical milestones for lead assets and a robust financial position that extends the company's operational runway.

Positives

• Tovecimig successfully met the primary endpoint of overall response rate in the COMPANION-002 Phase 2/3 study in patients with biliary tract cancer.
• CTX-8371 demonstrated strong clinical activity with three robust responses in heavily pre-treated patients with solid tumors and hematologic malignancies, including those who received prior checkpoint inhibitor therapies.
• The FDA cleared the IND submission for CTX-10726, allowing the Phase 1 study to open for enrollment in Q1 2026.
• A strong financial position with $209 million in cash and marketable securities at year-end 2025, which is expected to fund operations into 2028.
• Net proceeds of $129 million were generated from an underwritten public offering during 2025, significantly bolstering the cash position.
• Expansion of the leadership team with key promotions and new hires strengthens the company's strategic and operational capabilities.

Negatives

• Net loss increased to $66.5 million in 2025 from $49.4 million in 2024.
• Research and Development (R&D) expenses increased by 32% to $56.0 million in 2025.
• General and Administrative (G&A) expenses increased by 12% to $16.9 million in 2025.
• Net cash used in operating activities was $49 million during 2025.

Risks

• Ability to raise additional funding needed to continue pursuing business and product development plans.
• Inherent uncertainties associated with developing product candidates and operating as a development stage company.
• Ability to identify additional product candidates for development.
• Ability to develop, complete clinical trials for, obtain approvals for, and commercialize any product candidates.
• Competition in the industry in which the company operates.
• Market conditions.

Future Outlook

The company expects to report progression-free survival (PFS) and overall survival (OS) data for tovecimig in April 2026 and plans to initiate a Phase 2 study for tovecimig in broader DLL4+ tumor types in mid-2026. Initial data from CTX-8371 cohort expansions are anticipated in Q2 2026, with a new Hodgkin lymphoma cohort starting shortly. The Phase 1 study for CTX-10726 will open for enrollment in Q1 2026, with clinical data expected in the second half of 2026. A Phase 2 trial for CTX-471 is expected to initiate in mid-2026. The company anticipates its current cash and marketable securities will fund operations into 2028.

Management Comments

• Thomas Schuetz, MD, PhD, CEO: "2025 marked a year of significant progress for Compass, highlighted by our lead asset tovecimig successfully meeting the primary endpoint of overall response rate in the COMPANION-002 Phase 2/3 study in patients with biliary tract cancer. We are excited to report the results of the key secondary endpoints next month."
• Thomas Schuetz, MD, PhD, CEO: "The upcoming tovecimig PFS/OS data release could be transformational for the company, and we are looking forward to the new option it would bring for patients with biliary tract cancer."
• Thomas Schuetz, MD, PhD, CEO: "Our novel PD-1 x PD-L1 checkpoint inhibitor, CTX-8371, also demonstrated strong clinical activity this past year, with three robust responses in patients with both solid tumors and hematologic malignancies, all observed in heavily pre-treated patients who received prior checkpoint inhibitor therapies."
• Thomas Schuetz, MD, PhD, CEO: "2026 is poised to be a defining year for Compass, and we move forward with an expanded leadership team, welcoming Cyndi Sirard as CMO and Arjun Prasad as CCO, and promoting Bing Gong to CSO. Finally, our progress is bolstered by our strong financial position with $209 million of cash and marketable securities, providing runway into 2028."

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry, particularly in oncology, is highly competitive and capital-intensive. Compass Therapeutics' focus on bispecific antibodies targeting multiple pathways (DLL4/VEGF-A, PD-1/PD-L1, PD-1/VEGF-A, CD137) positions it within a growing area of cancer immunotherapy. The successful achievement of the primary endpoint for tovecimig and promising early responses for CTX-8371 are critical for a clinical-stage company, as these milestones can significantly de-risk pipeline assets and attract further investment, especially given the high failure rates in oncology drug development.

Comparison to Industry Standards

• The successful achievement of the primary endpoint (overall response rate) for tovecimig in the COMPANION-002 Phase 2/3 study for biliary tract cancer is a significant de-risking event, comparable to early-stage successes seen with other novel oncology agents like those from Mirati Therapeutics (e.g., KRAZATI for NSCLC) or Seagen (e.g., ADCETRIS for Hodgkin lymphoma) in their respective development phases.
• The reported "robust responses" for CTX-8371 in heavily pre-treated TNBC, NSCLC, and Hodgkin lymphoma patients, including those who failed prior checkpoint inhibitors, suggest potential differentiation in a crowded PD-1/PD-L1 space, similar to how companies like Regeneron (e.g., Libtayo) or Merck (e.g., Keytruda) have sought to expand indications or demonstrate efficacy in refractory settings.
• A cash runway into 2028 with $209 million is a strong financial position for a clinical-stage biotech, often exceeding the typical 12-18 month runway seen in smaller biotechs, and is more aligned with well-funded peers or those who have recently completed significant capital raises, such as those seen with companies like Moderna or BioNTech during their growth phases.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to significant clinical progress, extended cash runway, and potential for future value creation from pipeline assets.
• Patients (Biliary Tract Cancer): Potential for a new treatment option with tovecimig, pending PFS/OS data.
• Patients (TNBC, NSCLC, Hodgkin lymphoma, other solid tumors): Access to new experimental therapies through ongoing and opening clinical trials (CTX-8371, CTX-10726, CTX-471).
• Employees: Positive impact from company growth, expanded leadership team, and continued pipeline advancement, suggesting job stability and potential for career development.
• Creditors/Suppliers: Stable financial position with extended cash runway reduces immediate risk.

Next Steps

• Report PFS and OS analyses for tovecimig in April 2026.
• Initiate Phase 2 study of tovecimig in broader DLL4+ tumor types mid-2026.
• Present initial data from CTX-8371 cohort expansions at a major medical conference in Q2 2026.
• Begin a third expansion cohort for CTX-8371 in Hodgkin lymphoma patients shortly.
• Open Phase 1 study for CTX-10726 for enrollment in Q1 2026.
• Report clinical data from CTX-10726 Phase 1 study in the second half of 2026.
• Initiate Phase 2 trial of CTX-471 in patients with NCAM (CD56) expressing tumors mid-2026.

Key Dates

Recommendation

The company has achieved significant clinical milestones, including its lead asset meeting a primary endpoint and other candidates showing strong activity in heavily pre-treated patients. Coupled with a robust cash position extending into 2028, these factors substantially de-risk the company's pipeline and provide a strong foundation for future growth, making it an attractive investment for long-term growth in the oncology biopharmaceutical sector.

Keywords

Oncology, Biopharmaceutical, Clinical-stage, Antibody therapeutics, Tovecimig, CTX-8371, CTX-10726, CTX-471, Biliary tract cancer, Triple-negative breast cancer, Non-small cell lung cancer, Hodgkin lymphoma, DLL4, VEGF-A, PD-1, PD-L1, CD137, 4-1BB, Financial results, Pipeline update